异柠檬酸脱氢酶野生型胶质母细胞瘤切除中脑室进入的临床影响:一项多机构分析
该多机构回顾性研究纳入418例新诊断异柠檬酸脱氢酶野生型胶质母细胞瘤患者,278例(66.5%)发生脑室进入(VE),140例(33.5%)无VE。VE患者总生存期(OS)显著短于无VE者(18.6 vs 25.6个月,P=0.008),但按室管膜下区(SVZ)状态分层后,VE对OS无显著影响,且不增加并发症或非局部复发。作者认为外科医生可安全实施VE。
要点
- VE患者OS显著短于无VE者(18.6 vs 25.6个月,P=0.008)。
- 按SVZ状态分层后,VE对OS无显著影响。
- VE不增加症状性硬膜下积液、脑积水、感染或非局部复发。
核心结论
- 胶质母细胞瘤切除中VE不影响并发症或非局部复发,外科医生可安全实施VE。
研究设计与样本
- 多机构回顾性研究,纳入418例新诊断异柠檬酸脱氢酶野生型胶质母细胞瘤切除患者,按SVZ状态分析VE、并发症和复发模式。
主要发现
- VE患者OS显著短于无VE者(18.6 vs 25.6个月,P=0.008)。
- SVZ肿瘤中VE更常见(94.2% vs 非SVZ肿瘤26.3%,P<0.0001)。
- 44例非SVZ肿瘤患者发生VE,15例SVZ肿瘤患者未发生VE。
- SVZ肿瘤中,VE组OS为17.7个月 vs 无VE组19.9个月(P=0.34);非SVZ肿瘤中,VE组OS为30.8个月 vs 无VE组25.6个月(P=0.63)。
- 无论SVZ状态如何,VE不影响症状性硬膜下积液、脑积水、感染或非局部复发率。
关键数值与推荐
- VE患者OS 18.6个月 vs 无VE者25.6个月(P=0.008)。
- SVZ肿瘤VE发生率94.2% vs 非SVZ肿瘤26.3%(P<0.0001)。
- SVZ肿瘤中VE组OS 17.7个月 vs 无VE组19.9个月(P=0.34)。
- 非SVZ肿瘤中VE组OS 30.8个月 vs 无VE组25.6个月(P=0.63)。
临床怎么用
- 作者认为外科医生在SVZ和非SVZ胶质母细胞瘤切除中可安全实施VE。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Glioblastomas contacting the subventricular zone (SVZ) are associated with poor prognosis, and the impact of ventricular entry (VE) during resection remains controversial. Since glioblastomas with SVZ involvement often require VE, both SVZ involvement and VE are confounding factors. This study aimed to evaluate the effect of VE during glioblastoma resection by comparing patients with and without SVZ involvement. METHODS: This multi-institutional retrospective study reviewed newly diagnosed isocitrate dehydrogenase-wildtype glioblastoma who underwent resection. The focus was on VE, complications, and recurrence patterns based on SVZ status. RESULTS: A total of 418 patients were included with 278 (66.5%) undergoing VE and 140 (33.5%) without. Patients with VE had significantly shorter overall survival (OS) than those without VE (18.6 vs. 25.6 months, P = 0.008). VE was more common in patients with SVZ tumors (94.2%) compared to non-SVZ tumors (26.3%, P < 0.0001). Notably, 44 patients with non-SVZ tumors experienced VE, whereas 15 patients with SVZ tumors did not. Regardless of SVZ status, VE did not affect the rates of complications, such as symptomatic subdural effusion, hydrocephalus, infection, or nonlocal recurrence. OS was similar for each group: for SVZ tumors, OS was 17.7 months with VE versus 19.9 months without VE (P = 0.34), and for non-SVZ tumors, OS was 30.8 months with VE versus 25.6 months without VE (P = 0.63). CONCLUSIONS: VE during glioblastoma resection does not impact complications or nonlocal recurrence. Surgeons may safely perform VE during resection of both SVZ and non-SVZ glioblastomas without adverse effects.
引用
- Shimoda Y, Shibahara I, Kanamori M, et al. Clinical Effect of Ventricular Entry During Resection of Isocitrate Dehydrogenase-Wildtype Glioblastoma: A Multi-Institutional Analysis. World Neurosurg. 2025. PMID: 39793731. doi:10.1016/j.wneu.2024.123643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。